IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

ImmunityBio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$8.42−0.76 (-8.28%)

Close on Oct 19, 2026

Market cap: $8.84B
P/E (TTM): –
Dividend yield: –

ImmunityBio, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	113	15	0.62	0.24	0.93	0.61	2.20	0.05	0.05	0.04	0.24	0.64	0.60
Cost of Revenue	0.75	0	0	0	–	–	–	–	–	–	–	–	–
Gross Profit	113	15	0.62	0.24	–	–	–	–	–	–	–	–	–
Research & Development	–	190	232	248	196	140	112	56	42	29	11	1.60	0.45
Selling, General & Admin	–	169	130	103	135	71	46	43	57	95	228	4.62	2.42
Operating Expenses	–	359	363	352	331	221	158	98	99	125	239	6.22	–
Total Costs & Expenses	369	359	363	–	–	–	–	–	–	–	–	–	–
Operating Income	-256	-344	-362	-351	-330	-221	-156	-98	-99	-125	-239	-5.58	–
Interest Expense	61	115	129	64	15	9.07	5.92	–	0.62	0.07	0	0.47	0.46
Interest & Investment Income	–	–	–	–	–	1.23	1.64	2.32	4.23	5.17	0.31	0.02	0.00
Income from Equity Investments	0	0	-7.55	-12	-0.80	0	0	–	0	0	-0.06	0	–
Other Non-Operating Income	-96	-69	-222	-66	-20	-5.15	-4.01	1.66	2.20	3.12	1.70	-0.61	–
Asset Impairment Charges	–	–	–	–	–	0	0.87	0	0	0	0	0	–
Gain (Loss) on Investments	6.41	7.98	1.13	-3.09	-4.10	2.44	2.44	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	0.00	0	-0.21	-0.06	-0.02	0	0	–
Pretax Income	-352	-414	-584	-417	-350	-226	-160	-97	-97	-121	-237	-6.18	–
Income Tax Expense	-0.14	0	-0.04	0.03	0.01	-1.85	-0.11	-0.50	-0.49	-0.57	-0.30	0.00	0.00
Net Income incl. Noncontrolling Interests	-351	-414	-584	-417	-350	-224	-160	-96	-96	-121	–	–	–
Minority Interest in Earnings	-0.07	-0.08	-0.66	-0.75	-3.06	-2.34	-2.38	–	–	–	–	–	–
Net Income	-351	-414	-583	-417	-347	-222	-158	-96	-96	-121	-237	-6.19	-2.05
Net Income to Common	-351	-414	-583	-417	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-0.38	-0.59	-1.15	-1.04	-0.89	-0.59	-0.43	-1.22	-1.20	-1.47	-3.31	-0.75	-2.57
EPS (Diluted)(per share)	-0.38	-0.62	-1.15	-1.04	-0.89	-0.59	-0.43	-1.22	-1.20	-1.47	-3.31	-0.75	-2.57
Shares Outstanding (Basic, Weighted)(shares)	920	697	509	400	389	377	366	79	81	82	72	8.25	0.80
Shares Outstanding (Diluted, Weighted)(shares)	920	700	509	400	389	377	366	79	81	82	72	8.25	0.80
EBITDA	-241	-327	-344	-333	-316	-208	-142	-89	-94	-121	-237	-5.54	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 99.3%
Operating margin: -151.9%
Net margin: -598.6%
Return on equity, FY2025: 71.0%

Financial strength

Current ratio: 5.72
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 98.6%

Valuation

P/E ratio: –
Price to sales: 53.33
Price to book: –
Dividend yield: –